Recognition of non-operating income
ReproCELL Incorporated (the reporting company)
The research and development project under AMED's FY2025 open call program, “Project for Development of Fundamental Technologies for the Industrialization of Regenerative Medicine and Gene Therapy (Project for Promoting the Industrialization of Regenerative, Cellular and Gene Therapies),” and the foreign-currency-denominated deposits held by the Company
The subsidy income resulted from the grant amount for the research and development project being finalized and ¥89 million being received. The foreign exchange gain resulted from revaluing the foreign-currency-denominated deposits held by the Company at the exchange rate prevailing at the end of the period.
Subsidy income of ¥89 million and foreign exchange gains of ¥47 million, both recognized as non-operating income
The consolidated accounting period for the first quarter of the fiscal year ending March 2027 (1 April 2026 to 30 June 2026)
For the impact of this non-operating income on financial results and other related matters, please refer to the “Summary of Financial Results for the First Quarter of the Fiscal Year Ending March 2027 [Japanese GAAP] (Consolidated)” published today.
| Item | Details |
|---|---|
| Event name | Recognition of non-operating income |
| Date of occurrence | The consolidated accounting period for the first quarter of the fiscal year ending March 2027 (1 April 2026 to 30 June 2026; the foreign exchange gain arose from revaluation as of 30 June 2026, the end of the period) |
| Subject Entity | ReproCELL Incorporated (the reporting company) |
| Target Locations / Products | The research and development project under AMED's FY2025 open call program, “Project for Development of Fundamental Technologies for the Industrialization of Regenerative Medicine and Gene Therapy (Project for Promoting the Industrialization of Regenerative, Cellular and Gene Therapies),” and the foreign-currency-denominated deposits held by the Company |
| Cause | The subsidy income resulted from the grant amount for the research and development project being finalized and ¥89 million being received. The foreign exchange gain resulted from revaluing the foreign-currency-denominated deposits held by the Company at the exchange rate prevailing at the end of the period. |
| Amount of Impact on Business Performance | Subsidy income of ¥89 million and foreign exchange gains of ¥47 million, both recognized as non-operating income |
| Accounting period in which recognized | The consolidated accounting period for the first quarter of the fiscal year ending March 2027 (1 April 2026 to 30 June 2026) |
| Impact on Earnings Forecast | For the impact of this non-operating income on financial results and other related matters, please refer to the “Summary of Financial Results for the First Quarter of the Fiscal Year Ending March 2027 [Japanese GAAP] (Consolidated)” published today. |
Items this document does not state (17)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The subsidy income was recognized because the grant amount for the AMED research and development project was finalized and ¥89 million was received. The foreign exchange gain resulted from revaluing the foreign-currency-denominated deposits held by the Company at the exchange rate prevailing at the end of the period.